Table 4. Clinical data for pancreatic tissues analyzed.
| Patients | Age1 | Gender2 | TNM3 | ||
|---|---|---|---|---|---|
| T | N | M | |||
| PDAC 1 | 73 | F | 3 | 3 | 0 |
| PDAC 2 | 48 | F | 0 | 0 | 0 |
| PDAC 3 | 68 | F | 0 | 0 | 0 |
| PDAC 4 | 69 | M | 9 | 9 | 1 |
| PDAC 5 | 73 | F | 2 | 0 | 0 |
| PDAC 6 | 80 | M | 3 | 1 | 0 |
| CCP 1 | 74 | F | 3 | 1 | 0 |
| CCP 2 | 58 | F | 3 | 0 | 0 |
| IPMT 1 | 54 | M | 0 | 0 | 0 |
| IPMT 2 | 77 | M | 3 | 0 | 0 |
| NET | 85 | M | 3 | 1 | 0 |
| NET | 76 | F | 3 | 1 | 0 |
1: in years; 2:F, female; M, male; 3:TNM stage: T, tumor; N, node; M, metastasis. PDACs, pancreatic adenocarcinomas; CCP, chronic calcific pancreatitis; IPMT, intraductal papillary or mucinous tumor; NET, neuroendocrine pancreatic tumor.